Literature DB >> 2575084

The subcellular localization of the neu protein in human normal and neoplastic cells.

C R De Potter1, J Quatacker, G Maertens, S Van Daele, C Pauwels, C Verhofstede, W Eechaute, H Roels.   

Abstract

We have examined the subcellular localization of the neu protein by immunohistochemistry and immuno-electron microscopy, associated with immunoblotting of normal and neoplastic tissues with 2 monoclonal antibodies (MAbs). Immunoelectron microscopy clearly reveals that neu protein resides only on the lateral plasma membrane of the simple epithelium of the breast and on the plasma membrane of malignant breast cells. It is also found on the membranes of the microvilli and the apical vacuoles of the cells of the proximal convoluted tubule of the kidney. In the cytoplasm, the only immunoreactivity detected with both antibodies was on the membrane of the mitochondrial cristae of normal and malignant cells. Immunoblotting reveals that the molecular weight of the membrane protein is 185 and 155 kDa for the mitochondrial protein. The cell membrane staining pattern can be revealed by light microscopic immunohistochemistry only in malignant cells and is therefore specific for malignancy. The membrane expression in normal cells cannot be visualized in this way. The mitochondrial reactivity appears as a cytoplasmic granular staining when examined under the light microscope. Similar cytoplasmic staining has been described previously in other studies with other antibodies against the neu protein and has lead to speculation about its function in normal and malignant cells. However, it is demonstrated in this study that it is not the known neu-oncogene product.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2575084     DOI: 10.1002/ijc.2910440604

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Extracting functional information from tissues.

Authors:  M P DiGiovanna
Journal:  Mol Diagn       Date:  2001-03

2.  c-erbB-2 expression in different histological types of invasive breast carcinoma.

Authors:  S Soomro; S Shousha; P Taylor; H M Shepard; M Feldmann
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

3.  A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasion.

Authors:  C R De Potter; A M Schelfhout; F H De Smet; S Van Damme; L de Ridder; E Dhont; J van Emmelo
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

Review 4.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 5.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Pregnancy and breast cancer: a population-based study.

Authors:  W Reed; E Hannisdal; E Skovlund; S Thoresen; P Lilleng; J M Nesland
Journal:  Virchows Arch       Date:  2003-05-20       Impact factor: 4.064

7.  Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines.

Authors:  B L King; D Carter; H G Foellmer; B M Kacinski
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

8.  The p185erbB2 protein is localized on cell organelles involved in cell motility.

Authors:  C R De Potter; J Quatacker
Journal:  Clin Exp Metastasis       Date:  1993-11       Impact factor: 5.150

9.  Immunohistochemical study of neu protein overexpression in clinging in situ duct carcinoma of the breast.

Authors:  C R De Potter; M P Foschini; A M Schelfhout; C A Schroeter; V Eusebi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.